Daiichi Sankyo Co. Ltd.

History

Year	Detail
2005-2009
2005	The collaboration of Sankyo Co., Ltd. and Daiichi Pharmaceutical Co., Ltd founded the company.
2006	Daiichi Sankyo Co., Ltd. started manufacturing products in Daiichi Sankyo Healthcare Co., Ltd., Daiichi Sankyo, Inc., and Daiichi Sankyo Europe GmbH.
2007	Daiichi Sankyo Co., Ltd. started its business operations.
2008	Daiichi Sankyo Co., Ltd. acquired U3 Pharma GmbH of Germany and Ranbaxy Laboratories Ltd. of India.
2009	Daiichi Sankyo Co., Ltd. launched Prasugrel, an antiplatelet agent and global product in the U.S. and Germany.

2010-2014
2010	Daiichi Sankyo Co., Ltd. launched Rezaltas, a high-affinity ARB/long-acting calcium antagonist compound.
2011	Daiichi Sankyo Co., Ltd. acquired Plexxikon Inc., a pharmaceutical company in the U.S. This acquisition will accelerate Daiichi Sankyo's entry into the oncology market and strengthen its pipeline of providing advanced pharmaceuticals in core areas of unmet medical needs.
	Daiichi Sankyo Co., Ltd. launched Memary for treatment of Alzheimer's disease.
	Daiichi Sankyo Co., Ltd. launched Lixiana, an oral FXa inhibitor, and Nexium, a proton pump inhibitor.
2012	Daiichi Sankyo Co., Ltd. launched RANMARK, an antibody to target the RANK ligand, and TENELIA, a therapeutic agent for type II diabetes.
2014	Daiichi Sankyo Co., Ltd. acquired Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo.

2015-2019
2015	Sun Pharmaceutical Industries Ltd. has acquired Ranbaxy Laboratories Ltd. through the all-stock transition.
	Daiichi Sankyo Co., Ltd. launched Squarekids subcutaneous injection syringe.
2017	Daiichi Sankyo Co., Ltd. has launched CANALIA for treating type II diabetes mellitus, MINNEBRO for treating hypertension, and TURALIO for treating patients with tenosynovial giant cell tumors in Japan.

2020-Today
2020	Daiichi Sankyo Co., Ltd. launched ENHERTU to treat patients with HER2-positive unresectable and metastatic breast cancer in the U.S. and Japan.